Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 9, 7 (2003)
doi:10.1038/nm0103-7a
Biotech meets NIH to discuss poor disease markets
Alan Dove1
- Washington, D.C.
The diseases that have the biggest impact on global public health receive relatively minuscule amounts of government and corporate funding for research into new therapies. In December, representatives of funding organizations, biotechnology companies and research programs gathered in Washington, D.
To read this story in full you will need to login or make a payment (see right).
